Wave Life Sciences is trading 12.52% down at $5.31 after analysts cut its 2026 revenue forecast to $52 million from $59 million.
- Second-quarter revenue was $2.3 million versus a $7.65 million estimate, with an adjusted loss of $0.34 per share.
- Analysts lowered the consensus price target 13% to $19.06.
- The decline substantially exceeds broader market weakness, indicating a company-specific reaction; the stock remains actively traded during the August 11 session.